Article Versions Notes

Bertoli S, Dumas P-Y, Bérard E, Largeaud L, Bidet A, Delabesse E, Tavitian S, Gadaud N, Leguay T, Leroy H, et al. Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study. Cancers. 2020; 12(4):773. https://doi.org/10.3390/cancers12040773

Bertoli, Sarah, Pierre-Yves Dumas, Emilie Bérard, Laetitia Largeaud, Audrey Bidet, Eric Delabesse, Suzanne Tavitian, Noémie Gadaud, Thibaut Leguay, Harmony Leroy, and et al. 2020. "Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study" Cancers 12, no. 4: 773. https://doi.org/10.3390/cancers12040773

Bertoli, S., Dumas, P.-Y., Bérard, E., Largeaud, L., Bidet, A., Delabesse, E., Tavitian, S., Gadaud, N., Leguay, T., Leroy, H., Rieu, J.-B., Vial, J.-P., Vergez, F., Lechevalier, N., Luquet, I., Klein, E., Sarry, A., De Grande, A.-C., Récher, C., & Pigneux, A. (2020). Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study. Cancers, 12(4), 773. https://doi.org/10.3390/cancers12040773